Agilent Technologies Inc. Microarrays Used in Groundbreaking Prenatal Research Study

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE:A) today announced its microarrays were used in a landmark research study on prenatal samples. The three-year study was designed to evaluate the accuracy, efficacy and potential advantages of using microarray analysis as compared with conventional karyotyping. Agilent SurePrint CGH microarrays and analysis software were used for the majority sample cohort of 4,400 samples.

Back to news